Quick answers
- What is Nadolol used for?
- The FDA-approved label (Nadolol, BluePoint Laboratories, September 7, 2026) says: “Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Nadolol have a boxed warning?
- The label we quote has no boxed warning, but 13 of 24 FDA labels for this medicine do. Check the label of your own product.
- Is there a shortage of Nadolol?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Nadolol been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Nadolol?
- 16 companies list prescription products of Nadolol in the FDA NDC Directory, including BluePoint Laboratories, Bryant Ranch Prepack and VGYAAN Pharmaceuticals LLC.
What Nadolol is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. …
— FDA label: Nadolol, BluePoint Laboratories, effective September 7, 2026. Read the full label on DailyMed →
The FDA has 24 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
13 of 24 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 53 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| nadolol 20 mg tablet | Generic | $0.1274 per tablet |
| nadolol 40 mg tablet | Generic | $0.2540 per tablet |
| nadolol 80 mg tablet | Generic | $0.3160 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- BluePoint Laboratories9 products
- Bryant Ranch Prepack6 products
- VGYAAN Pharmaceuticals LLC3 products
- Alembic Pharmaceuticals Limited3 products
- Alembic Pharmaceuticals Inc.3 products
- Amneal Pharmaceuticals NY LLC3 products
- Exelan Pharmaceuticals Inc.3 products
- Unichem Pharmaceuticals (USA), Inc.3 products
- Zydus Pharmaceuticals USA Inc.3 products
- American Health Packaging3 products
- Cipla USA Inc.3 products
- Aurobindo Pharma Limited3 products
- Golden State Medical Supply, Inc.3 products
- Zydus Lifesciences Limited3 products
- A-S Medication Solutions1 product
- Remedyrepack Inc.1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (7)
- ANDA201893Aurobindo Pharma · September 16, 2015
- ANDA203455Invagen Pharms · December 18, 2015
- ANDA208832Amneal Pharms Co · June 2, 2017
- ANDA207761Zydus Pharms · July 28, 2017
- ANDA210955Regcon Holdings · July 23, 2018
- ANDA212856Somerset Theraps LLC · September 13, 2019
- ANDA211763Alembic · June 2, 2023
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0464-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Nadolol Tablets, USP 40 mg 100 Tablets Rx Only NDC 69097-868-07 Manufactured for: Cipla USA Inc. 9100 S. Dadeland Blvd., Suite 1599 Miami, FL 33156 — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 198006, 198007, 198008 |
|---|---|
| SPL set ID of the quoted label | f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f |
| FDA labels (SPL) | 24 |
| FDA applications | 7 ANDA |
| Active ingredients (FDA) | NADOLOL |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Nadolol, BluePoint Laboratories, effective September 7, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →